Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRBN | Q96SW2 | 17/20 | 0.48 |
| ▸ | DDB1 | Q16531 | 10/20 | 0.48 |
| ▸ | GSPT1 | P15170 | 8/20 | 0.48 |
| ▸ | IKZF3 | Q9UKT9 | 1/20 | 0.48 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.38 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.38 |
| ▸ | CA12 | O43570 | 1/20 | 0.37 |
| ▸ | CA1 | P00915 | 1/20 | 0.37 |
| ▸ | CA2 | P00918 | 1/20 | 0.37 |
| ▸ | CA7 | P43166 | 1/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | THRB | P10828 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22929098 | 0.89 | CRBN (0.60) | CRBNDDB1GSPT1IKZF3CYP2C19 | |
| SCHEMBL22929043 | 0.87 | CRBN (0.65) | CRBNDDB1GSPT1IKZF3CYP2C19 | |
| SCHEMBL22929094 | 0.84 | CRBN (0.48) | CRBNDDB1GSPT1IKZF3CYP2C19 | |
| SCHEMBL22929044 | 0.81 | CRBN (0.63) | CRBNDDB1GSPT1IKZF3CYP2C19 | |
| SCHEMBL22929083 | 0.76 | CRBN (0.45) | CRBNDDB1GSPT1IKZF3 | |
| SCHEMBL22929058 | 0.76 | CRBN (0.73) | CRBNDDB1GSPT1IKZF3CYP2C19 | |
| SCHEMBL22929045 | 0.76 | CRBN (0.81) | CRBNDDB1GSPT1IKZF3CYP2C19 | |
| SCHEMBL19523152 | 0.75 | CRBN (0.53) | CRBNDDB1GSPT1IKZF3CYP2C19 | |
| SCHEMBL20427485 | 0.75 | CRBN (0.64) | CRBNDDB1GSPT1IKZF3CYP2C19 | |
| SCHEMBL20183148 | 0.75 | CRBN (0.47) | CRBNDDB1GSPT1IKZF3CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10905684-B2 | Aminoamide compounds | BIOTHERYX, INC. (US) | 2021-02-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10905684-B2 | Aminoamide compounds | DNPEP, BCAT2, AADAT | CRBN 2355/4885DDB1 1072/4885GSPT1 662/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.